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Abstract
Background: Genome-wide changes in DNA methylation are an epigenetic phenomenon that can
lead to the development of disease. The study of global DNA methylation utilizes technology that
requires both expensive equipment and highly specialized skill sets.
Methods: We have designed and developed an assay, CpGlobal, which is easy-to-use, does not
utilize PCR, radioactivity and expensive equipment. CpGlobal utilizes methyl-sensitive restriction
enzymes, HRP Neutravidin to detect the biotinylated nucleotides incorporated in an end-fill
reaction and a luminometer to measure the chemiluminescence. The assay shows high accuracy and
reproducibility in measuring global DNA methylation. Furthermore, CpGlobal correlates
significantly with High Performance Capillary Electrophoresis (HPCE), a gold standard technology.
We have applied the technology to understand the role of global DNA methylation in the natural
history of lung cancer. World-wide, it is the leading cause of death attributed to any cancer. The
survival rate is 15% over 5 years due to the lack of any clinical symptoms until the disease has
progressed to a stage where cure is limited.
Results: Through the use of cell lines and paired normal/tumor samples from patients with non-
small cell lung cancer (NSCLC) we show that global DNA hypomethylation is highly associated with
the progression of the tumor. In addition, the results provide the first indication that the normal
part of the lung from a cancer patient has already experienced a loss of methylation compared to
a normal individual.
Conclusion: By detecting these changes in global DNA methylation, CpGlobal may have a role as
a barometer for the onset and development of lung cancer.
Published: 3 August 2008
BMC Cancer 2008, 8:222 doi:10.1186/1471-2407-8-222
Received: 9 March 2008
Accepted: 3 August 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/222
© 2008 Anisowicz et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2008, 8:222 http://www.biomedcentral.com/1471-2407/8/222
Page 2 of 12
(page number not for citation purposes)
Background
The functional role of DNA methylation includes main-
taining the stability of chromosomes, silencing repetitive
sequences, arresting the deleterious effects of integrated
foreign DNA and controlling gene expression [1].
Genome-wide loss of the methyl group at 5-methyl
cytosines (hypomethylation) leads to the destabilization
of the DNA [2]. Global DNA hypomethylation has been
observed to be one of the earliest molecular abnormalities
described in human neoplasia [3,4]. This biological phe-
nomenon could be exploited to gain an insight into the
mechanism of action of DNA methylation to determine
how it plays a role not only in disease but also in aging,
diet and efficacy of drugs.
Several technologies have been developed to measure the
methyl content of the genome. In general the techniques
have been focused around the use of methodologies that
can quantitate the 5-methyl cytosines using reversed-
phase high performance liquid chromatography (RP-
HPLC), two dimensional thin layer chromatography (2D-
TLC), high performance liquid chromatography-mass
spectrometry (HPLC-MS), high performance capillary
electrophoresis (HPCE) and liquid chromatography-elec-
trospray ionization-tandem mass spectrometry (LC-ESI-
MS/MS) [5-10]. These approaches represent the gold
standards of measuring global DNA methylation but lack
the capacity for high-throughput sample handling,
require expensive equipment to analyze the material and
involve highly specialized skill sets. Other approaches
that have been developed to quantitate the global 5-
methyl cytosines include radio-labeling the CpG sites
using M.SssI methyltransferase, methyl-C antibody, pyro-
sequencing and methyl sensitive restriction enzymes [11-
17]. We have developed an approach that has been
adapted from a method that uses methyl sensitive restric-
tion enzymes. These enzymes have been used to define
the methylation status of both the whole genome and spe-
cific regions using a host of technologies [14-17]. In this
paper we present CpGlobal, a non-radioactive, non-PCR,
high-throughput approach to measure global DNA meth-
ylation. It describes how CpGlobal is performed in a
microtiter plate, which enables multiple samples to be
analyzed simultaneously. Furthermore, this paper illus-
trates how the assay utilizes biotinylated nucleotides to
provide a highly accurate and reproducible method that
can measure global DNA methylation using only 100 ng
of genomic DNA per reaction. In addition, we demon-
strate that CpGlobal is an excellent alternative to HPCE,
one of the gold standard technologies.
CpGlobal has been employed to study the role of global
DNA methylation in lung cancer to understand further the
biology of this disease. It is the world's most common
fatal cancer with an overall survival rate of 15% over 5
years [18]. This dismal outcome can be attributed to the
natural history of the disease where in its early stages it is
asymptomatic and in the latter stages patients present
with non-specific symptoms [19]. In order to gain further
insight into the natural history of this disease we meas-
ured global DNA methylation in a set of lung cancer cell
lines that represented all the stages of this disorder as well
as in 20 paired normal/tumor from patients diagnosed
with Non-small cell lung cancer (NSCLC). The resultant
data showed that there was an increase in hypomethyla-
tion observed with tumor progression as well as in the
normal part of the lung from cancer patients.
Methods
Measurement of Global DNA Methylation
To quantitate the amount of DNA methylation in any
genome 100 ng of a sample was aliquoted nine times into
a 96 well white Microfluor 2 plate (Thermo Electron,
Waltham, MA). The genomic DNA in the first three wells
was digested with 5 units of a methyl-sensitive restriction
enzyme such as HpaII (New England BioLabs, Beverly,
MA), the DNA in the second three wells was digested with
5 units of the methyl-insensitive restriction enzyme MspI
(New England BioLabs, Beverly, MA) to normalize the
data when calculating the Global DNA Methylation Index
(GDMI), and the third set of triplicates was for buffer only
(NEBuffer1 – New England BioLabs, Beverly, MA). All
reactions were performed in a total volume of 30 μl. Prior
to incubation the 96 well microtiter plate was sealed with
Adhesive PCR Foil (ABgene Inc., Rochester, NY) using an
ALPS 300™ (ABgene Inc., Rochester, NY), spun briefly and
placed in an air incubator for 3 hours at 37°C. After incu-
bation, the plate was spun briefly and the Adhesive PCR
Foil removed. The digestion of DNA was followed by an
end-fill reaction where 20 μl of biotinylation buffer con-
taining Biotin-11-dCTP and Biotin-11-dGTP (Perkin
Elmer, Boston, MA) and Sequenase (USB Corporation,
Clevland, OH) in 40 mM Tris-HCl, pH 7.5, 20 mM Tris-
HCl, 50 mM NaCl) was added. The final concentration of
biotinylated dCTP and dGTP and Sequenase used per well
was 0.1 μM and 0.1 units respectively. The plate was
sealed, spun briefly and placed into an air incubator for
30 minutes at 37°C. After the incubation period the plate
was spun briefly, the Adhesive PCR Foil removed and 100
μl of Reacti-Bind™ DNA Coating Solution (Pierce, Rock-
ford, IL) was added to each well. After mixing, the plate
was once again sealed and placed on an orbital platform
shaker (Lab-Line Instruments Inc., Melrose Park, IL) and
shaken at 150 RPM at room temperature overnight. The
solution in the wells was removed and the wells were
washed 4 times with TBS (10 mM Tris-HCL pH 8.0, 150
mM NaCl). The biotin was detected using HRP Neutravi-
din (Pierce, Rockford, IL) and the DNA Detector kit (KPL,
Gaithersburg, MD). Briefly, 200 μl of the Detector Block
Solution (KPL, Gaithersburg, MD) was added to each wellBMC Cancer 2008, 8:222 http://www.biomedcentral.com/1471-2407/8/222
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and the plate was incubated for 30 minutes at room tem-
perature. After removal of the Detector Block Solution,
150 μl of Detector Block Solution containing 0.5 μg/ml
(1:2000 dilution) of HRP Neutravidin was added to each
well and the plate was incubated at room temperature for
30 minutes. The Detector Block/HRP Neutravidin solu-
tion was removed and the wells washed 5 times with
1xBiotin wash solution (KPL, Gaithersburg, MD). After
the final wash 150 μl of LumiGlo® chemiluminescence
substrate (KPL, Gaithersburg, MD) was added to each
well. After 2 minutes the luminescence emitted from each
well was quantitated by a Wallac Envision 2100 multila-
bel reader (Perkin Elmer, Boston, MA).
Generation of fully methylated lambda DNA
To determine the analytical sensitivity of CpGlobal the
entire genome of Lambda DNA was methylated using
M.SssI (New England BioLabs, Beverly, MA), a bacterial
CpG methylase, which methylated all the cytosine resi-
dues that resided within a CpG dyad. Fifty micrograms of
lambda genomic DNA was methylated with M.SssI for 4
hours at 37°C. The salt and enzyme were removed from
the methylated lambda DNA using QIAEX II (Qiagen,
Valencia, CA). To determine whether the lambda DNA
was fully methylated 1 μg of the product was aliquoted
and digested with MspI (methyl insensitive restriction
enzyme) and another microgram with HpaII (a methyl
sensitive restriction enzyme). The digested products were
analyzed by gel electrophoresis. No fragments were
observed in the HpaII digested lane. The expected size
bands were measured in the MspI digested lane.
Linearity of CpGlobal using lambda DNA
To determine the efficiency of digestion and end-fill reac-
tions for an amount of lambda genomic DNA, we used
the methyl-insensitive restriction enzyme MspI (CCGG)
for which there were 328 restriction sites in the genome.
The genomic DNA was aliquoted six times into a 96 well
microtiter Microfluor 2 White plate. One set of triplicates
were digested with MspI (New England BioLabs, Beverely,
MA), the second set was treated with buffer only
(NEBuffer2 – New England Biolabs, Beverely, MA). A
range of DNA concentrations (25 ng, 12.5 ng, 6.25 ng,
3.12 ng) were assayed to determine the linearity of CpGlo-
bal. The assay and the quantitation of the chemilumines-
cence were performed as described above. The net
luminescence per DNA concentration was plotted and 25
ng of lambda DNA was determined to provide the appro-
priate signal to noise level for the next set of experiments.
Accuracy of CpGlobal using lambda DNA
To ascertain the accuracy of CpGlobal and determine the
best methyl-sensitive restriction enzyme that could be
applied to this assay, a series of mixtures with increasing
ratios of unmethylated to methylated Lambda DNA was
generated. The series of mixtures increased by 5% such
that the range of methylated to unmethylated produced a
broad spectrum of DNA methylation densities that varied
from 100% to 0% methylated. Once the mixtures were
generated, 25 ng of each DNA mix was aliquoted nine
times into a 96 well microtiter Microfluor 2 White plate.
To quantitate the amount of methylated Lambda DNA in
each mixture the first three aliquots were digested with 5
units of a methyl-sensitive restriction enzyme (AciI, BstUI
HpaII, HinP1I, HypCH4IV) (New England BioLabs, Bev-
erely, MA), the second three aliquots were digested with 5
units of the methyl-insensitive restriction enzyme MspI
(New England BioLabs, Beverely, MA) and the third three
aliquots were mixed with buffer only. The following NEB
buffers (New England Biolabs, Beverely, MA) were used
for different enzymes: NEBuffer1 (HpaII, MspI,
HpyCH4IV), NEBuffer2 (BstUI and HinP1I) and
NEBuffer3 (AciI). The assay and the quantitation of the
chemiluminescence were performed as described above
except for BstUI. This enzyme is a blunt end cutter and
instead of using Sequenase during the end-fill reaction 0.1
units Klenow (New England BioLabs, Beverely, MA) was
used in its stead. Here, the 3'-5'exonuclease activity of the
Klenow was utilized to chew back into the blunt end-frag-
ment and then the 5'-3'exonuclease activity would incor-
porate the biotinylated nucleotides.
Quantitative Range of CpGlobal using human genomic 
DNA
The linear range of the CpGlobal assay for human
genomic DNA was determined by measuring global DNA
methylation in human male genomic DNA isolated from
whole blood (Novagen, San Diego, CA). A range of DNA
concentrations (100 ng, 50 ng, 25 ng, 12.5 ng, 6.25 ng and
3.125 ng) were assayed to determine the linearity of
CpGlobal. One set of triplicates were digested with HpaII
(New England BioLabs, Beverely, MA), the second set with
MspI (New England BioLabs, Beverely, MA) and the third
set was treated with buffer only (NEBuffer1 – New Eng-
land Biolabs, Beverely, MA). The assay and the quantita-
tion of the chemiluminescence were performed as
described above.
Cell Culture and DNA Isolation
All cell lines were purchased from ATCC (Manassas, VA)
and were grown according to the manufacturer's recom-
mendations. The cell lines that were used to compare the
CpGlobal with High Performance Capillary Electrophore-
sis (HPCE) were SW48 (CCL-231), LoVo (CCL-229), HT-
29 (HTB-38) and NCI-H69 (HTB-119D). Assessment of
the global DNA methylation was performed on Non-
Small Cell Lung Cancer tumor cell lines from various
stages of lung cancer. These included a normal lung NL20
(CRL-2503), Stage I NCI-H1703 (CRL-5889), Stage II
NCI-H522 (CRL-5810), Stage IIIa NCI-H1993 (CRL-BMC Cancer 2008, 8:222 http://www.biomedcentral.com/1471-2407/8/222
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5909), Stage IIIb NCI-H1944 (CRL5907) and Stage IV
metastatic liver NCI-H1755 (CRL-5892). All cells were
grown in 75 cm2 cell culture flasks (Corning Incorporated,
Corning, NY) in 5% CO2 at 37°C. Cells were harvested
when they had reached 90% confluency. DNA was iso-
lated using the Blood and Cell Culture DNA Midi Kit
(Qiagen, Valencia, CA). The purity and concentration of
the DNA was measured using a DU650 spectrophotome-
ter (Beckman Coulter, Fullerton, CA). The quality of the
DNA was determined by loading 200 ng on a 1% agarose
gel to inspect for any degradation.
Lung Tissue samples
Twenty fresh frozen tissues samples, including lung
tumors and areas of non involved lung, were obtained
from a repository of biological specimens through the
lung cancer Specialized Program of Research Excellence
(SPORE) at the Vanderbilt Ingram Cancer Center. For
each specimen, a quality control of the tissue specimen
was obtained from hematoxylin and eosin stained tissue
section on adjacent tissue and reviewed by a pathologist
prior to analysis. De-identified clinical data elements were
shared in compliance of the health insurance portability
and accountability regulations. This study was approved
by the local Institutional Review Board of both institu-
tions.
Normal lung DNA
Normal lung DNA from young male accident victims was
purchased from BioChain Institute, Inc., Hayward, CA.
DNA isolation
Approximately 0.1 gm lung tissue from biopsies of paired
tumor and normal tissue from NSCLC patients was frozen
in liquid nitrogen. The tissue was pulverized to a fine
powder using a freezer mill 6750 (SPEX SamplePrep,
Metuchen, NJ) according to the manufacturer's recom-
mendations. DNA was prepared using the Blood and Cell
Culture DNA midi kit (Qiagen, Chatsworth, CA). The
DNA was checked for concentration and purity by reading
the absorbance at 260 and 280 nM and was further tested
for intactness by running 100 ng on a 1% agarose gel.
Linear Regression Analysis
Linear regression analyss was performed using EXCEL
Analysis ToolPak Regression Analysis. In each case pre-
sented single predictor variable was used. R square,
Adjusted R square, intercept, coefficient, standard error
and F significance were generated by standard Summary
Report. Residual Plots and LineFit Plots were used to
check for the linearity of the regression.
Calculation of Global DNA Methylation Index (GDMI)
To determine the net luminescence, the average value for
the no enzyme control was subtracted from the individual
enzyme values. To calculate the global DNA methylation
index (GDMI), the individual net luminescence values for
the methylation sensitive enzyme were divided by the
average Msp I net luminescence. All calculations were per-
formed in Microsoft Excel.
Statistical Analysis
Both means and medians were calculated when compar-
ing group differences among Normal Non-Disease, Nor-
mal Disease and Tumor samples. Only medians were used
when the distributions of continuous variables were sig-
nificantly skewed by small sample sizes such as different
histopathological groups. Due to the potential compro-
mise of parametric assumption, non-parametric Wil-
coxon/Kruskal-Wallis tests were applied to evaluate the
statistical significances for all analysis. P-value <= 0.05
was considered as statistically significant and p-value >
0.05 and <= 0.10 was regarded as border-line significant.
All analyses were conducted using JMP5.1 (SAS Institute,
Inc., Cary, NC).
Results
Design of CpGlobal
CpGlobal was designed to incorporate several key features:
easy to use, did not require radioactivity or PCR, func-
tioned in a 96-well microtiter plate and utilized equip-
ment that most laboratories possessed. The design was
adapted from a method that utilizes methyl-sensitive
restriction enzymes [14], which when applied to genomic
DNA would produce a set of digested fragments that could
be quantitated and translated into an amount of DNA
methylation present in the genome. We have modified the
approach by performing all the steps in one 96 well
microtiter plate. Therefore, once the genomic DNA from a
sample was aliquoted into the well of the microtiter plate
it remained in that location through the four stages of
treatment: digestion, end-fill with biotinylated nucle-
otides, attachment to the surface of the well and chemilu-
minescence. The methyl-insensitive restriction enzyme
MspI, the isoschizomer of HpaII, was used in the design
to normalize the data collected from the methyl-sensitive
restriction enzymes. This step aided in the removal of any
intrinsic variations introduced through slight differences
in DNA concentrations, and digestion and end-fill reac-
tions. As such a global DNA methylation index (GDMI)
was calculated. The arrangement of the DNA in the 96
well microtiter plate was designed so that up to 10 sam-
ples per plate could be analyzed (Figure 1). The final step
in the assay was the measurement of luminescence
through the use of a luminometer. The end-product was
an assay designed for an operator to easily manage the
measurement of global DNA methylation in multiple
samples, without the need for radioactivity, PCR and
expensive equipment.BMC Cancer 2008, 8:222 http://www.biomedcentral.com/1471-2407/8/222
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Accuracy of CpGlobal
Based on the design of the assay we began with the appli-
cation of CpGlobal on Lambda DNA with the aim to
determine which methyl-sensitive restriction enzyme was
the best indicator in measuring global DNA methylation.
Two species of lambda DNA were created: one that was
unmethylated and the other that was in vitro methylated
using M.SssI, a CpG methylase. Five 4 base pair methyl-
sensitive restriction enzymes, AciI (CCGC), BstUI
(CGCG), HpaII (CCGG), HinP1I (GCGC) and
HypCH4IV (ACGT), were chosen based on their fre-
quency within the Lambda genome and the core recogni-
tion sequence site. These enzymes were used to digest a
series of Lambda DNA mixtures, which consisted of 21
points that extended from 100% to 0% methylated in 5%
intervals. GDMI was generated for each 5% increment,
which was compared against the theoretical methylation
level. A linear regression analysis was performed for each
Schematic showing design of CpGlobal Figure 1
Schematic showing design of CpGlobal.
Calculate GDMI
Aliquot genomic DNA from sample
End-fill with biotinylated dGTP and dCTP
HRP Neutravidin to detect biotin
Methyl-
sensitive
enzyme
Methyl-
insensitive
enzyme
Buffer
only
Attach DNA to surface of well
Chemiluminescence (Luminometer)
Treat DNA
End-fill with biotinylated dGTP and dCTP
HRP Neutravidin to detect biotin
Methyl-
sensitive
enzyme
Methyl-
insensitive
enzyme
Buffer
only
Attach DNA to surface of well
Chemiluminescence (Luminometer)
Table 1: Linear regression analysis to determine which methyl-sensitive restriction enzymes were effective in CpGlobal.
Enzyme Theoretical Regression Actual Regression Adjusted R Square Standard Error F significance
AciI y = 1.57-1.57x y = 0.45-0.46x 0.86 0.06 1.11E-09
BstUI y = 0.48-0.48x y = 0.09-0.11x 0.87 0.01 4.39E-10
HinP1I y = 0.66-0.66x y = 0.95-0.89x 0.97 0.05 1.24E-15
HpaII y = 1.00-1.00x y = 0.94-0.95x 0.96 0.06 4.46E-15
HpyCH4IV y = 0.44-0.44x y = 0.74-0.73x 0.97 0.04 7.67E-17
Theoretical regression formulas were calculated based on the number of recognition sites in lambda DNA for each of the methyl-sensitive 
restriction enzymes-AciI: 516, BstUI: 157, HinP1I: 215, HpaII and the isoschizomer MspI: 328, and HpyCH4IV: 143. The Actual regression formulae 
were calculated based on the regression analysis using the theoretical methylation level as a predictor for the results from CpGlobal.BMC Cancer 2008, 8:222 http://www.biomedcentral.com/1471-2407/8/222
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methyl-sensitive restriction enzyme (Table 1). We
observed a highly significant correlation of GDMI with
the theoretical methylation levels using HinP1I, HpaII
and HypCH4IV. Thus, under these conditions the use of
any one of these three methyl-sensitive restriction
enzymes would be an effective indicator for global DNA
methylation.
Application of CpGlobal in human genomic DNA
In order to quantitate global DNA methylation in the
human genome it was essential that the assay operates
within the linear range. In particular, it was important to
determine if the performance of a methyl-sensitive and
the methyl-insensitive restriction enzyme was linear with
DNA concentration as the net luminescence generated
from the assay would be used to calculate the GDMI. Sub-
sequently, CpGlobal was applied to human genomic DNA
isolated from whole blood. Using a two-fold serial dilu-
tion that ranged from 100 ng to 3.125 ng, the DNA for
each concentration was digested in triplicate with HpaII,
MspI and treated with buffer only. The net luminescence
from each experiment was plotted against DNA concen-
tration (Figure 2a). The results demonstrated a linear
regression that correlated highly with DNA concentration
and net luminescence (R2  HpaII = 0.982, R2  MspI =
0.999). The GDMI was calculated for human whole blood
DNA and was plotted against DNA concentration. The
GDMI was moderately consistent with DNA concentra-
tion (Figure 2b). We chose to use 100 ng of human
genomic DNA in all the following experiments because
the signal to background ratio was at least > 10 fold.
Comparison of CpGlobal with High-performance capillary 
elecrophoresis (HPCE)
HPCE is viewed as one of the gold standard technologies
when measuring the global genomic content of 5-methyl-
cytosine [8]. We applied CpGlobal to calculate the GDMI
from a selection of cancer cell lines to determine whether
a strong correlation existed between these two technolo-
gies. We measured the global DNA methylation in four
cancer cell lines (SW48, LoVo, HT-29 and H69), which
varied in methyl content from high to low as determined
by HPCE. HpaII and MspI were utilized on 100 ng of cell
line genomic DNA to calculate the GDMI. The HPCE
results, extracted from the publication by Paz et al [20]
were compared with the calculated GDMIs from the four
cell lines. The CpGlobal results presented with a good lin-
ear fit when compared to the HPCE data. In addition, we
observed that the number of unmethylated HpaII sites
had an inverse linear relationship with the total number
of methylated cytosines (data not shown).
The linear fit for this correlation was calculated:
HPCE = -6.2 × GDMI + 7.18
Adjusted R2 = 0.77
Residual error = 0.36.
Considering that the HPCE data were taken from a publi-
cation to create the correlation, these results demon-
strated that CpGlobal could be utilized as an alternative
technique to one of the gold standard technologies.
Application of CpGlobal to lung cancer lines
We directed the assay toward measuring the association of
global DNA methylation with the natural history of lung
cancer. Lung cancer is measured in 5 stages, which range
from 0 to IV [21]. We measured the GDMI, using the
HpaII methyl-sensitive restriction enzyme, in epithelial
cell lines that represented the full extent of the disease:
Normal lung, Stage I, Stage II, Stage IIIa, Stage IIIb and
Stage IV metastatic liver. The results indicated that there
was an increase in global DNA hypomethylation that was
associated with the progressive development of the tumor
(Figure 3). The greatest loss of methylation was observed
in the Stage IIIb cell line and the least was measured in the
Stage I. Compared with the normal epithelial cell line, this
represented a loss of 5-methylcytosines that ranged from
10%, in an early stage tumor, to 50% in a late stage cancer.
These data demonstrated the quantitative capacity of
CpGlobal to measure changes in global DNA methylation
in a cancer as it progresses from early to late stage and
metastasis.
Global DNA methylation levels in normal tissue and lung 
cancer
We measured the GDMI using CpGlobal in lung DNA
from 20 patients diagnosed with Non Small Cell Lung
Cancer (NSCLC) (Table 2) and 12 normal individuals to
ascertain whether global DNA hypomethylation is a
prominent phenomenon in this disease. DNA from three
types of lung tissues was analyzed: Normal Non-Disease
from normal individuals, Normal Disease (pathological
and histological defined normal) paired with Tumor from
each cancer patient. The GDMI was measured in the lung
DNAs using the methyl-sensitive restriction enzymes
HinP1I, HpaII and HypCH4IV. A general trend was
observed when the median GDMI was calculated for all
three methyl-sensitive enzymes (Table 3a); an increase in
the median GDMI was measured with lowest levels
detected in the Normal Non-Diseased and the highest in
the Tumors (median GDMI – Normal Non-Disease < Nor-
mal Disease < Tumor). Nonparametric Wilcoxon/Kruskal-
Wallis test was performed on the median GDMI data to
determine whether the observed trend was statistically sig-
nificant (Table 3b). The greatest difference in GDMI was
between the Normal Non-Disease and Tumor (p < 0.054–
0.004), which was observed in all three methyl-sensitive
enzymes. However, only HinP1I and HpaII were able toBMC Cancer 2008, 8:222 http://www.biomedcentral.com/1471-2407/8/222
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Assessment of CpGlobal using human genomic DNA isolated from whole blood Figure 2
Assessment of CpGlobal using human genomic DNA isolated from whole blood. A) Linearity of CpGlobal for differ-
ent amounts of lymphocyte DNA. Twofold serial dilutions of genomic DNA from 100 ng down to 3.12 ng digested with HpaII 
or MspI. Net Luminescence of the no enzyme control is subtracted from the net luminescence of HpaII and MspI and plotted 
versus concentration of DNA. The points fit with a linear regression (HpaII R2 = 0.982 and Msp I R2 = 0.999). B) Net HpaII 
luminescence was divided by net MspI luminescence to get global DNA methylation index (GDMI) and plotted versus DNA 
concentration.
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Measurement of global DNA methylation in a set of lung cancer cell lines that represents the various stages of the disease Figure 3
Measurement of global DNA methylation in a set of lung cancer cell lines that represents the various stages of 
the disease. 100 ng genomic DNA was digested with HpaII and MspI and the GDMI calculated: Lane 1, NL20 (normal lung); 
lane 2, NCI-H1703 (Stage 1 NSCLC); lane 3, NCI-H522 (Stage 2 NSCLC); lane 4, NCI-H1993 (stage 3A NSCLC); lane 5, NCI-
H1944 (Stage 3B NSCLC); lane 6, NCI-H1755 (Stage 4 NSCLC).
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Table 2: Patient information
Pathology
Patient ID Age Race Gender Tumor Lymph Node Metastasis Stage Differentiation
1 64 White Male T2 N0 Mx Stage IB Non-well Diff
2 59 White Female T1 N0 M0 Stage IA Non-well Diff
3 85 White Female T1 N0 M0 Stage IA Non-well Diff
4 62 White Male T1 N0 Mx Stage IA Well Diff
5 62 White Male T1 N1 Mx Stage IIB Non-well Diff
6 53 White Male T1 N0 M1 Stage IA N/A
7 68 White Female T1 N0 Mx Stage IA Well Diff
8 60 Black Female T1 N0 M0 Stage IA Non-well Diff
9 54 White Male T2 N0 Mx Stage IB Non-well Diff
10 77 White Female T2 N0 M0 Stage IA Non-well Diff
11 71 White Female T1 N2 M1 Stage IIIA Well Diff
12 47 Black Female T3 N/A N/A Stage IIIA N/A
13 57 White Female T4 N0 M0 Stage IB Non-well Diff
14 65 White Female T1 N0 M0 Stage IA Non-well Diff
15 77 White Male T2 N0 M0 Stage IB Non-well Diff
16 82 White Male T1 N0 Mx Stage IA Non-well Diff
17 85 White Male T2 N0 Mx Stage IB Non-well Diff
18 52 White Male T2 N0 M0 Stage IB Non-well Diff
19 63 White Male T2 N0 M0 Stage IA Non-well Diff
20 56 White Male T2 N0 M0 Stage IB Non-well DiffBMC Cancer 2008, 8:222 http://www.biomedcentral.com/1471-2407/8/222
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detect a GDMI difference between the paired Normal Dis-
ease and Tumor (p = 0.064 and p = 0.068 respectively).
Out of the three methyl-sensitive enzymes only HpaII was
observed to distinguish between the Normal Non-Disease
and Normal Disease with statistical significance (p =
0.039). These results suggested that the histological and
pathological defined normal part of the lung from a can-
cer patient had altered global DNA methylation levels.
Distinguishing Properties of CpGlobal in Lung Cancer
To investigate further the changes in global DNA methyl-
ation in lung cancer we separated the major histopatho-
logic characteristics assigned to the cancer patient samples
Table 3: Median GDMI of normal non-disease, normal disease and the paired tumors for different  methyl-sensitive restriction 
enzymes
A
Median GDMI of normal non-disease, normal disease and the paired tumors for different methyl-sensitive restriction enzymes.
Sample Type HinP1 I HpyCH4 IV Hpa II
Normal Non-Disease 0.163 0.304 0.293
Normal Disease 0.197 0.368 0.321
Tumor 0.216 0.427 0.379
B
Non-parametric tests of normal disease versus paired tumor, normal non-disease versus normal disease, and normal non-
disease versus tumor for each of the methyl-sensitive restriction enzymes.
Comparisons HinP1 I HpyCH4 IV Hpa II
Normal Disease vs Tumor 0.068* 0.201 0.064*
Normal Non-Disease vs Normal 
Disease
0.483 0.129 0.039**
Normal Non-Disease vs Tumor 0.005** 0.054* 0.004**
Numbers in bold with asterisks indicate statistical significance of Wilcoxon/Kruskal-Wallis tests with threshold of p <= 0.05 (**) or p <= 0.10 (*).
Table 4: Median GDMI stratified by different histopathologic characteristics for normal disease, tumor, and their ratios.
Characteristics Enzymes Normal Disease p-value Tumor p-value Tumor/Normal Disease p-value
(Median) (Median) (Median)
Stage Stage IA 
(n = 10)
Stage IB 
(n = 7)
Stage IA 
(n = 10)
Stage IB 
(n = 7)
Stage IA 
(n = 10)
Stage IB 
(n = 7)
HinP1I 0.20 0.15 0.22 0.18 0.26 0.005** 0.92 1.74 0.006**
HypCH4IV 0.37 0.37 0.92 0.39 0.43 0.59 1.05 1.33 0.08*
HpaII 0.31 0.32 0.49 0.35 0.44 0.13 1.20 1.32 0.19
Grade of 
Differentiation
Well Diff 
(n = 3)
Nonwell Diff 
(n = 15)
Well Diff 
(n = 3)
Nonwell Diff 
(n = 15)
Well Diff 
(n = 3)
Nonwell Diff 
(n = 15)
HinP1I 0.20 0.20 0.31 0.19 0.25 0.17 1.11 1.21 0.86
HypCH4IV 0.37 0.37 0.77 0.29 0.44 0.10* 0.79 1.14 0.04**
HpaII 0.31 0.32 0.68 0.28 0.41 0.01** 0.82 1.33 0.01**
Tumor Size T1
(n = 10)
T2
(n = 8)
T1
(n = 10)
T2
(n = 8)
T1
(n = 10)
T2
(n = 8)
HinP1I 0.20 0.16 0.66 0.18 0.25 0.04** 0.99 1.47 0.04**
HypCH4IV 0.37 0.35 0.59 0.39 0.42 0.70 1.01 1.15 0.12
HpaII 0.32 0.32 0.62 0.32 0.43 0.08* 1.14 1.31 0.17
Numbers in bold with asterisks indicate statistical significance of non-parametric Wilcoxon/Kruskal-Wallis tests with a threshold of p <= 0.05 (**) 
or p <= 0.10 (*).BMC Cancer 2008, 8:222 http://www.biomedcentral.com/1471-2407/8/222
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into three groups (Stage – 1A and 1B, grade of differentia-
tion – well and non-well and tumor size – T1 and T2) and
searched for any association of the GDMI with these char-
acteristics in the Normal Disease and Tumor samples.
Nonparametric Wilcoxon/Kruskal-Wallis test was per-
formed using the median GDMI data, which was meas-
ured in the Normal Disease and Tumor samples. No
statistically significant changes were observed in global
DNA methylation from the Normal Disease tissue sam-
ples for any methyl-sensitive restriction enzyme when
compared against the three groups. However, the median
GDMI from the Tumor tissue samples was significantly
associated with all three histopathologic characteristics. In
particular this was observed for HinP1I (Stage 1A versus
1B), HypCH4IV and HpaII (well versus non-well differen-
tiated) and HinP1I and HpaII (T1 versus T2) (Table 4).
When the analysis was performed using the ratio of
median GDMI Tumor/median GDMI Normal Disease the
statistical significance was improved for some methyl-sen-
sitive restriction enzymes and made worse for others
when compared against the three histopathologic charac-
teristics (Table 4). These analyses indicated that global
DNA hypomethylation remained a persistent observation
in lung tissue from patients diagnosed with NSCLC. Fur-
thermore, CpGlobal could clearly distinguish a difference
in the Tumor samples between Stage 1A and 1B, tumor
size T1 and T2, and well differentiated and non-well dif-
ferentiated tissue.
Discussion
To actively study the role of global DNA methylation in
the context of disease requires complex and expensive
equipment and skill sets that compliment the technology.
We have designed and developed a technique, CpGlobal,
which is easy-to-use, cost-effective and used skill sets and
equipment that were present in most molecular biology
laboratories. The assay did not require radioactivity or
involve PCR. We found that CpGlobal correlated signifi-
cantly with HPCE, which was one of the gold standard
technologies used to measure global DNA methylation.
Considering that the HPCE global DNA methylation data
was retrieved from a publication [20], where the cell cul-
ture conditions may not have been similar to our stand-
ards, these results exemplified the quality of CpGlobal to
measure the methyl content of a genome.
The use of certain methyl-sensitive restriction enzymes in
this assay provided CpGlobal with a level of accuracy and
reproducibility in the measurement of global DNA meth-
ylation. The methyl-sensitive enzymes that worked con-
sistently were HpaII and HinP1I. While the performance
of HypCH4IV was not as effective in our assay as the other
two methyl-sensitive restriction enzymes, the recognition
sequence ACGT made it unique compared to HpaII and
HinP1I, which were CpG rich sites. Therefore, such a mix-
ture of methyl sensitive restriction sites allowed a greater
assessment of the genome's global methyl content.
The application of CpGlobal in a 96 well microtiter plate
enabled multiple samples to be analyzed at once. We rou-
tinely assayed each sample in triplicate. As such 10 sam-
ples were measured at a time. Yet, by performing the assay
in duplicate up to 16 samples could be incorporated into
the 96 well microtiter format. In addition, we have
extended the use of the assay to function in a 384 well
microtiter plate, which shared the same characteristics as
the 96 well format (data not shown). Here, up to 64 sam-
ples could be analyzed at once. However, the application
of robotics to dispense the liquids would be more practi-
cal in this format. While the data presented in this paper
were obtained from the assay where 100 ng of genomic
DNA per well was used, the results showed that using as
little as 3 ng could be utilized. However, we have observed
that the signal to background ratio diminishes as less
DNA is used (data not shown).
The ability to access high quality tissue to perform these
experiments was one of the limiting factors. While the tis-
sue that was obtained from patients with lung cancer was
highly defined and scored by experts that are knowledge-
able in the histology and pathology of lung cancer, the
normal tissue was obtained from car crash victims. To
acquire detailed information regarding normal tissue is
often difficult and limited. The variability in the tissue
from accident victims can cause irreproducibility in global
DNA methylation data. This may be reflected in the time
and cause of death. In addition, it may explain why the
median GDMI data from the Normal Non-Disease tissue
were slightly higher than expected. The importance of col-
lecting high quality tissue from normal individuals out-
side of blood is an on-going issue. A well-defined normal
tissue bank, where sex and age matched samples could be
obtained, which could go hand-in-hand with patient
material, would be invaluable for diagnostic studies that
seek the ability to use tissue beyond blood. An additional
factor, which may have influenced the data, could be the
purity of the tumor from the matched patient material.
While the tumor was matched with normal it was not
micro-dissected and so heterogeneity could have been an
issue. Nevertheless, while the median GDMI for the tumor
tissue was greater that the matched Normal Disease it was
not as high as expected and this may have been attributed
to heterogeneity. Given the difficulties faced in this study
in acquiring truly well defined tissue, the data still
remained convincing and strongly suggested CpGlobal
was able to clearly discern differences in global DNA
methylation from Normal Non-Disease and Normal Dis-
ease clinical samples.BMC Cancer 2008, 8:222 http://www.biomedcentral.com/1471-2407/8/222
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The application of CpGlobal in a disease environment
provided an opportunity to ascertain the value of the tech-
nology as a research tool. In particular, how global DNA
hypomethylation contributed to the instability of the
genome and in the transformation of a cell from normal
to disease. Genome-wide loss in methylation has been
observed as one of the earliest known molecular abnor-
malities in human neoplasias [3]. This would suggest that
a better understanding of this biological phenomenon
may provide an insight into the evolution of cancer [4]. In
that regard, we have applied CpGlobal to lung cancer to
delve deeper into understanding the natural history of this
disease. Through the use of samples from patients diag-
nosed with NSCLC, two major observations from these
studies were construed. The first, demonstrated that there
was a statistically significant loss of global DNA methyla-
tion as the tumor progressed from Stage 1A to 1B (p =
0.08–0.006). At this early stage in the disease the only
other characteristics for a pathologist to stage the lung
cancer is size and grade of differentiation of the tumor.
Both of these were associated with global DNA
hypomethylation (p = 0.04 and p = 0.04 – 0.01 respec-
tively). The second suggested that the histological and
pathological defined normal part of the lung had incurred
a loss in global DNA methylation that was statistically sig-
nificant when compared with normal individuals (p =
0.039). Considering the small sample size in this study,
and that by histopathologic standards the non tumor lung
tissue from the cancer patients were graded as normal,
global DNA hypomethylation appears to be a measurable
change. Also, several studies have observed global DNA
hypomethylation in other normal disease tissues such as
colon, breast and ovary [22-24]. In addition, this phe-
nomenon was determined to be a whole tissue circum-
stance rather than a cell-by-cell event [24-26]. It is
plausible to speculate that a tissue-wide loss in global
DNA methylation suggests that the entire lung is in a pre-
neoplasia state. Continued global DNA hypomethylation
could be one of the key factors in driving the cells to
become malignant. However, how much global DNA
hypomethylation is required before malignant transfor-
mation occurs would require a longitudinal prospective
study to be performed.
Exploiting these global DNA methylation changes may be
of value in screening asymptomatic individuals who are at
risk in developing lung cancer. An initial practical applica-
tion would be to measure the global DNA methylation
levels of a large sample set that contained prospective
patient material. One type of sample set that could be
used is from a prospective nested case control study such
as the one that was utilized to measure the methylation
status of the promoters from 14 genes in proximal sputum
samples. Here, methyl sensitive PCR (MSP) was the tech-
nique applied to these samples. The results showed that
this technique could detect changes 18 months prior to
diagnosis with a 64% sensitivity and specificity [27].
Application of CpGlobal to this type of material may
improve the result through combining the results of both
global DNA methylation and region specific analysis
using MSP. Furthermore, it may provide information as to
the association of global DNA methylation and the natu-
ral history of the disease before the presence of any clini-
cal symptoms.
Conclusion
CpGlobal is an easy-to-use technique to study the biolog-
ical role of global DNA methylation in the cell. The tech-
nique can be used in almost any practical laboratory
without the need for expensive equipment or highly spe-
cialized skill sets. In addition, CpGlobal can be utilized as
a research tool to investigate the epigenetic phenomenon
in disease, aging, diet, efficacy of drugs and in any other
vertebrate or invertebrate genome where methylation is
employed. The application of CpGlobal to measure the
changes in global DNA methylation in lung cancer has
demonstrated that there exists a distinguishing difference
between Normal Non-Disease and Normal Disease tissue.
Such a change should be examined further and exploited
to understand the functional role of this epigenetic phe-
nomenon with the potential aim of providing a diagnostic
for asymptomatic individuals who are at risk of develop-
ing lung cancer.
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